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Abstract
Neuroendocrine tumors (NETs) of the thorax including bronchial and thymic tumors belong to foregut NETs. Limited loco-re-
gional thoracic NETs can be resected with surgery, but in extensive metastatic disease the treatment is mainly palliative. A high 
incidence and density of somatostatin receptors (SSTR2, SSTR3, and SSTR5) are found in thoracic NETs. The purpose of this 
study was to evaluate the role of SPECT-CT somatostatin receptor scintigraphy (SRS) with 99mTc-Tektrotyd for imaging, staging 
and follow up of patients with bronchial and thymic neuroendocrine tumors.
Forty-one patients with thoracic tumors with neuroendocrine differentiation were studied. Sixty-eight examinations including 
SPECT-CT studies of the neck and chest and/or abdomen and pelvis were carried out 2–4 hrs. post i.v. administration of aver-
age 740 MBq activity dose of 99mTc-EDDA/HYNIC-TOC (Tektrotyd, Polatom). In all 41 investigated patients we obtained 81.25% 
(13/16), 88% (22/25) and 85.36% (35/41) of sensitivity, specificity and accuracy of this diagnostic approach, respectively. 
Somatostatin-receptor scintigraphy correctly identified all primary NETs located in the lungs and thymus. SPECT-CT studies 
with 99mTc-EDDA/HYNIC-TOC resulted in exact pre-surgical and pre-treatment N/M staging of bronchial and thymic NETs, except 
2 cases with multiple hepatic metastases and 1 with massive suprarenal metastasis. It can be concluded that SPECT-CT with 
99mTc-EDDA/HYNIC-TOC is a valuable tool for staging and follow-up of patients with thoracic NETs.
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Introduction
Neuroendocrine tumors (NETs) of the thorax including bronchial 
and thymic tumors belong to foregut NETs. Carcinoid bronchial 
tumors are an uncommon group (2%) of all lung neoplasms and 
approximately 20–30% of all NETs, developing from neuroendocrine 
enterochromaffin or Kulchitsky cells, located in the bronchial mu-
cosa [1–3]. Primary neuroendocrine tumors of the thymus account 
for less than 5% of all anterior mediastinal neoplasms and 2% of 
thymic lesions [4–6]. Bronchial NETs are classified according to 
the grade of biological aggressiveness (G1–G3) and the extent of 
tumor cell differentiation (well-differentiated/ poorly-differentiated). 
The well-differentiated neoplasms comprise typical (G1) and atypi-
cal (G2) carcinoids. Large-cell neuroendocrine carcinomas as well 
as small-cell carcinomas (G3) are poorly differentiated [1, 2]. Pri-
mary neuroendocrine thymic tumors were recognized for the first 
time in 1972 by Rosai and Higa [7]. Moran and Suster indicated that 
thymic neuroendocrine carcinomas are closely related neuroendo-
crine neoplasms that can display a variable spectrum of differentia-
tion. They also highlighted the generally more aggressive nature 
of these tumors when arising in mediastinal location [8]. These 
tumors can be divided adequately based on their histopathologic 
features into well-differentiated, moderately differentiated, and 
poorly differentiated neoplasms [6, 8].
Limited loco-regional thoracic NETs can be resected with sur-
gery, but extensive metastatic disease is mainly treated palliatively. 
Patients with carcinoid and/or paraneoplastic syndromes caused 
by advanced thoracic NETs should be treated individually in order 
to control hormonal oversecretion and to improve their quality of 
life [1, 2, 4]. Serum markers such as chromogranin A (CgA) and 
neuron specific enolase (NSE) are important additional tools for 
follow up of NETs patients [1, 2]. Except the histological classifi-
cation, the assessment of other parameters is critical for correct 
staging according Union for International Cancer Control, UICC, 
7th TNM-classification [1, 2, 4]. A high incidence and density of 
somatostatin receptors (SSTR2, SSTR3, and SSTR5) are found 
in thoracic NETs [9, 10]. Several somatostatin analogs with high 
affinity to these receptors have been developed for diagnosis and 
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therapy [11–17]. According to the ENETS recommendations 2015, 
the functional hybrid PET-CT and SPECT-CT imaging modalities with 
radiolabeled somatostatin analogs has important role in diagnosis, 
staging and follow up of patients with bronchial and mediastinal 
NETs, since these methods are more specific than conventional im-
aging techniques especially for typical and atypical carcinoids [2]; 
somatostatin-receptor SPECT-CT/PET-CT studies can also predict 
the response to peptide receptor radionuclide therapy (PRRT) [1, 2]. 
Recently, the somatostatin receptor scintigraphy (SRS) technique 
SPECT-CT with 99mTc-EDDA/HYNIC-TOC (99mTc-Tektrotyd, Polatom) 
has been approved in Bulgaria for diagnostics of NETs [18–20]. 
This tracer has high affinity to SSTR2 and lower to SSTR3 and 
SSTR5. Optimal physical parameters and biodistribution of 
99mTc-labelled somatostatin analog, lower physiological uptake in 
the liver and bowel, lower radiation burden and one-day imaging 
protocol are its advantages over 111In-pentetreotide [19, 20]. Fusion 
SPECT-CT images improve image quality, anatomical localization, 
morphological characteristics of scintigraphic “hot” spots and pro-
vide differential diagnosis of the most uncertain lesions, reducing 
false positive and false negative results and thus improving specific-
ity and accuracy of somatostatin-receptor SPECT studies [19, 20].
The purpose of this study was to evaluate the role of SPECT-CT 
somatostatin-receptor scintigraphy with 99mTc-99mTc-EDDA/ 
/HYNIC-TOC for imaging, staging and follow up of patients with 
bronchial and thymic neuroendocrine tumors.
Material and methods
Forty-one patients, (27 males/14 females) with neuroen-
docrine bronchial and thymic tumor differentiation: 50–100% 
positive-staining tumor cells were studied during the period June, 
2012–June 2016: 
 — with large-cell neuroendocrine carcinomas; 
 — with small-cell neuroendocrine carcinomas — SCLC; 
 — 5 with lung carcinoids (typical and atypical); 
 — with thymic NETs; 
 — with metastatic lesions from tumor with unknown primary origin 
(UPO), expressed neuroendocrine markers, suspected for lung 
neuroendocrine origin.
Patients were referred to SRS SPECT-CT because of the clini-
cal, radiological and/or biochemical suspicion of thoracic NETs. 
Plasma chromogranin A (CgA) level was measured. Thirty-six 
patients underwent somatostatin-receptor scintigraphy for initial 
staging, whereas 5 patients with metastatic neuroendocrine le-
sions with UPO were examined in order to visualize location of 
primary bronchial NET. Immunohistochemistry with commonly used 
neuroendocrine markers such as chromogranin A, synaptophysin, 
TTF1 and CD56 was performed in all 41 patients after surgical treat-
ment or bronchoscopy. Proliferation index Ki67 was established for 
differentiation of low-grade (G1, G2) versus high-grade (G3) NETs. 
Fifteen patients, in whom the locally advanced and metastatic 
disease was found, were followed up by control SRS SPECT-CT 
during therapy with cold somatostatin analogs. During the follow 
up patients were examined after 4 weeks of withdrawal of “cold” 
long acting somatostatin analog, if applicable.
Sixty-eight examinations including SPECT-CT studies of the 
neck and chest and/or abdomen and pelvis were carried out 
2–4 hrs. post i.v. administration of average 740 MBq activity dose 
of 99mTc-EDDA/HYNIC-TOC (Tektrotyd, Polatom). SPECT-CT gamma 
camera Symbia T2, Siemens, was used for topographic localization 
and morphological substratum of “hot” abnormal foci. Double-head 
SPECT acquisition included 64 projections, 25 s/projection, matrix 
256x256. Low dose CT scanning was performed in the helical 
mode. Acquisition parameters included settings at 130 KeV; 30 mA; 
3–5 mm slice thickness. The images were interpreted based on all 
other clinical and radiological data.
Results
Primary lung neuroendocrine tumors were visualized in 5 pa-
tients with UPO, proven histologically. Primary bronchial and thymic 
NETs were imaged in all other 36 patients showing intensive tracer 
uptake, sensitivity of SRS was 100% (Figure 1–3). Correct pre-treat-
ment N and M staging according to the UICC 7th TNM-classification 
was performed in studied patients. Loco-regional supraclavicular, 
mediastinal and hilar lymphadenopathy were imaged in 16/41 
cases (Figure 1–3). Distant liver, pulmonary, bone and/or suprarenal 
positive metastatic lesions overexpressing somatostatin recep-
tors were visualized in 15/41 cases, showing a good correlation with 
increased level of Chromogranin-A (Figures 4 and 5). There was no 
tracer uptake in the liver multiple secondary lesions in 1 patient with 
large-cell neuroendocrine bronchial tumors and in 1 with atypical 
carcinoid, visualized on the CT part of hybrid SPECT-CT images, 
maybe due to metastatic cell dedifferentiation and insufficient 
expression of somatostatin receptors (Figure 1). Enlarged supra-
renal glands in 1 case were negative because of tumor necrosis. 
Diagnostic performance of SRS in the studied group is summarized 
in Table 1. Fifteen patients with locally advanced and extended 
disease were followed-up after the complex treatment. Somato-
statin receptor scintigraphy with 99mTc-EDDA/HYNIC-TOC was very 
useful to assess SSTR expression in order to predict an individual 
response to therapy with somatostatin analogs and thus to plan 
PRRT in individuals with non-operable thoracic NETs. SPECT-CT 
studies were performed to evaluate the effect of therapy according 
to revised RECIST guideline, version 1.1. [21]. Functional imaging 
results were compared with biochemical markers such as CgA.
 — complete therapeutic response after surgical treatment 
was obtained in 2 patients with locally advanced lung NETs: 
the negative scan of the thorax was obtained with normaliza-
tion of CgA level; 
 — partial response — in 4 pts: ≥ 30% decrease in the sum of the 
longest diameters of 2 target lesions compared with baseline 
or disappearance of > 50% of hot spots; 
 — stable disease — in 6 pts: persistence of one or more le-
sions and/or the maintenance of decreased tumor marker level 
of CgA above the basic value (Figure 5); 
 — progressive disease — in 3 pts: appearance of one or more new 
lesions and/or unequivocal progression of existing lesions. Lo-
cal relapse after surgery was observed in one patient (Figure 4). 
Progression of the disease was observed in 1 case with atypical 
and in another with large-cell neuroendocrine bronchial tumor, 
but liver metastases were false negative, imaged only on the 
CT projection of SPECT-CT study — scheme of chemotherapy 
was changed. In one case the presence of a malignant tumor 
did not correlate with biochemical findings — level of CgA 
was < 100 ng/ml, (normal range 1–100 ng/ml).
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Figure 1. Male (51-year-old), with hepatic meta from NET with UPO. SPECT-CT showed exact topographic location of the primary pulmonary 
carcinoid in the right lung (A) and ipsilateral hilar (B) and mediastinal lymphadenopathy (C) (N-staging), with intensive tracer uptake, significant of 
SSTR overexpression. Some of liver mets showed low tracer uptake because of cell dedifferentiation (D). Immunohistochemistry confirmed atypical 
carcinoid (F) with synaptophysin (H), TTF-1 (E) and CD56 (G) positive markers
Figure 2. Female (61-year-old). SPECT-CT showed exact topographic location of the primary pulmonary carcinoid in the left lung and bilateral 
hilar and mediastinal lymphadenopathy (N-staging) with intensive tracer uptake, significant of SSTR overexpression (A). Immunohistochemistry 
confirmed small-cell lung cancer with positive synaptophysin (B) and CD56 (C) markers
A B C D
E F G H
Atypic carcinoid, TTF-1 x 20 Atypic carcinoid, Ki67 = 25% x 20 Atypic carcinoid, CD56 x 20 Atypic carcinoid, Synaptophysin x 20
SCLC, CD56 x 20
SCLC, Synaptophysin x 20
C
B
A
High tracer uptake was observed in 2 benign tumors — in 
1 suprarenal adenoma and in 1 thyroid adenoma. In one case 
positive benign ovary cyst was visualized due to the presence of 
inflammatory condition (Figure 6). Intensive physiological uptake 
was shown in the both breasts of 2 young women (< 45-year-old) 
due to fibrocystic alteration, in 2 pts with accessory spleen and in 
the region of the pancreatic duct and bowel.
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Figure 3. Female (52-year-old), with thymic NET. SPECT-CT showed exact topographic retrosternal location of the primary NET in the 
anterior mediastinum (A) and mediastinal lymphadenopathy (B) (N-staging) with intensive tracer uptake, significant of SSTR overexpression. 
Immunohistochemistry confirmed mediastinal NET, G3 (G) with synaptophysin (D), TTF-1 (E) and CK7 (C) positive markers but CgA negative 
expression (F) — typical for low differentiated with high malignancy NETs. 3. Control study 6 month later after chemotherapy in the same patient. 
SPECT-CT showed enlarged primary thymic tumor with d = 77 mm with central necrotic part without tracer uptake (H, I), persistence of mediastinal 
lymphadenopathy (J, K) and new pleural metastatic lesion on the right significant for disease progression
A B
EDC F G
H
J
I
K
Mediastinal NET, 
CK7 x 10
Mediastinal NET, 
Synaptophysin x 10
Mediastinal NET, 
TTF-1 x 10
Mediastinal NET, 
CgA x 10
Mediastinal NET, 
H&E x 10
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In all 41 investigated patients we obtained 81.25% (13/16), 
88% (22/25) and 85.36% (35/41) of sensitivity, specificity and 
accuracy of this diagnostic approach, respectively. 
Discussion
Our data confirmed the published results of other studies that 
somatostatin receptor scintigraphy correctly identified all pri-
mary NETs located in lung and thymus [11, 22]. SPECT-CT stud-
ies with 99mTc-EDDA/HYNIC-TOC resulted in exact pre-surgical and 
pre-treatment N/M staging of bronchial and thymic NETs, except 
in one case where total massive bilateral suprarenal metastatic 
lesions were detected only on the CT part of SPECT-CT images with-
out tracer uptake and in two cases with negative multiple hepatic 
lesions. These results were described as false negative, probably 
due to necrotic process and metastatic cell dedifferentiation with 
Figure 4. Male (40-year-old), operated due to NET of the left lung with bronchoplasty. In 2013 — hepatic meta from NET proven after biopsy; 
CgA = 700 ng/ml. SPECT-CT showed relapse in the region of bronchoplasty (A, B) with hepatosplenomegaly, 2 lesions in the liver and a lot of 
bone lesions (C, D), overexpressing SSTR. Immunohistochemistry confirmed Large Cell NET with positive TTF-1 (E), synaptophysin (F) and CgA 
expression (G); Ki67 = 20% (H). Chemotherapy and Sandostatin LAR x 30 mg/28 d were considered
Large Cell NET, TTF-1 x 10 Large Cell NET, 
Synaptophysin x 10
Large Cell NET, 
CgA x 10
Ki67 = 20% x 10
A B
E
DC
F G H
Figure 5. Female (26-year-old), operated due to pulmonary carcinoid; elevated CgA = 177 ng/ml. Control SPECT-CT showed exact topography 
and size of two secondary hepatic lesions overexpressing SSTR (A). Somatostatin-receptor scintigraphy performed after 6 applications of 
30 mg/28 d Sandostatin LAR showed the same number, location, size and tracer uptake (B, C). CgA = 148 ng/ml — stable disease
A B C
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absence of somatostatin-receptor expression [10–22]. Positive 
imaging results concerning benign thyroid adenoma and suprarenal 
adenoma could be explained with moderate somatostatin-receptor 
expression, described in some benign tumors and inflammation [10, 
22, 23]. Some authors reported that 111In-octreotide scintigraphy 
failed to identify all liver metastatic lesions maybe because density 
of somatostatin receptors is much lower in metastatic cells origi-
nated from more aggressive histological types of pulmonary 
NETs such as large-cell neuroendocrine lung cancer [10, 22, 23]. 
Clinical role of SRS SPECT-CT imaging in patients with 
NETs can be summarized as follows [1, 19, 20]: (1) Anatomical 
cross-sectional SPECT-CT data increase specificity and sensitiv-
ity of standard somatostatin-receptor scintigraphy because of 
their excellent spatial resolution and improved imaging quality. 
(2) SPECT-CT images provide excellent anatomic characterization 
and localization of the most of unclear scintigraphic “hot” spots in 
order to differentiate malignant from benign lesions and physiologi-
cal uptake, and thus improve the diagnostic accuracy of SPECT 
images with 99mTc-labeled somatostatin analogs.
In our results, the advantage of SRS SPECT-CT with 99mTc-99mTc-EDDA/ 
/HYNIC-TOC was to visualize primary bronchial and thymic tumors in 
case of metastatic lesions from tumor with unknown primary origin 
and to assess SSTR expression status in order to predict an individual 
response to therapy with somatostatin analogs and thus effectively 
plan PRRT in patients with non-operable and metastatic thoracic 
NETs. However, in the diagnosis of primary NETs the SRS has limited 
role and might be useful only in selected cases, to depict the most 
appropriate tumor lesion for correct biopsy in the thorax.
SRS SPECT-CT with 99mTc-99mTc-EDDA/HYNIC-TOC was also 
useful for pre-treatment correct N&M staging of NETs according 
to the UICC 7th TNM classification, except imaging of liver meta-
stases, and in the follow-up of patients after the treatment: (1) for 
monitoring of functional and morphological treatment response 
according to revised RECIST guideline, version 1.1. (Eur J Cancer 
2009; 45: 228–247): as complete, partial, stable or progressive di-
sease, (2) for differential diagnosis of malignant lesions from benign 
tumors and physiological activity especially in the regions below 
the diaphragm, (3) for early determination of local relapse or recur-
rence in cases with negative anatomical imaging (CT, MRT) but 
with clinical and biochemical indications for presence and extent of 
NETs, (4) for precise topography of metastatic foci in patients with 
disease extension. However, in patients with negative SRS, PET-CT 
studies should be performed.
It can be concluded that SPECT-CT with 99mTc-Tektrotyd is a valu-
able tool for staging and follow-up of patients with NETs localized 
in the thorax.
A B C
Figure 6. Thyroid adenoma in the left lobe (A), positive benign cyst of the left ovary (B) and benign adenoma of the left suprarenal gland (C) with 
intensive tracer uptake
Table 1. Diagnostic performance of SRS in the studied group
SRS Results Patient No Lymph node metastases Liver metastases Bone metastases Suprarenal metastases
True positive 13 13 7 6 2
True negative 22 0 0 0 0
False positive 3 3 0 0 0
False negative 3 0 2 0 1
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